Clinical and laboratory characteristics of study participants
| Characteristic . | Patients with KAD (n = 42) . | PWH (n = 12) . | P value . |
|---|---|---|---|
| Age, y | 41 (32.3-54.0) | 35.5 (31.8-38.5) | .083 |
| Male, n (%) | 41 (97.6) | 11 (91.7) | .923 |
| Race, n (%) | |||
| Hispanic | 5 (11.9) | 5 (41.7) | .055 |
| African/African-American | 17 (40.5) | 5 (41.7) | 1.000 |
| White | 16 (38.1) | 1 (8.3) | .108 |
| Other | 4 (9.5) | 1 (8.3) | 1.000 |
| BMI (kg/m2) | 23.6 (21.1-26.5) | 23.8 (22.4-28.0) | .47 |
| Time from ART initiation to sample collection (wk) | 31.3 (5-263) | 48.6 (48-51) | .80 |
| CD4 T cells per μL | 208 (74-357) | 246 (227-304) | .440 |
| CD19 B cells per μL | 124 (50-242) | NA | NA |
| Hemoglobin (g/dL) | 10.0 (8.5-11.5) | 12.8 (11.4-13.8) | .001 |
| Platelets (×103/μL) | 219 (115-328) | 258 (218-287) | .448 |
| HIV-VL (log10 IU/mL) | 1.8 (0.7-3.0) | 0.9 (0.7-1.8) | .078 |
| Ferritin (ng/mL) | 696 (376-1520) | 29 (17-38) | <.001 |
| CRP (mg/L) | 33.7 (10.5-73.8) | 2.0 (1.3-2.3) | <.001 |
| KSHV-VL (log10 copies per million cells) | 3.6 (2.7-4.6) | NA | NA |
| KAD subgroups, n | NA | NA | |
| KS | 10 (23.8) | ||
| MCD ± KS | 11 (26.1) | ||
| MCD and PEL ± KS | 5 (11.9) | ||
| KICS + KS | 11 (26.1) | ||
| PEL | 5 (11.9) | ||
| Prior therapy | 18 (42.9) | NA | NA |
| Characteristic . | Patients with KAD (n = 42) . | PWH (n = 12) . | P value . |
|---|---|---|---|
| Age, y | 41 (32.3-54.0) | 35.5 (31.8-38.5) | .083 |
| Male, n (%) | 41 (97.6) | 11 (91.7) | .923 |
| Race, n (%) | |||
| Hispanic | 5 (11.9) | 5 (41.7) | .055 |
| African/African-American | 17 (40.5) | 5 (41.7) | 1.000 |
| White | 16 (38.1) | 1 (8.3) | .108 |
| Other | 4 (9.5) | 1 (8.3) | 1.000 |
| BMI (kg/m2) | 23.6 (21.1-26.5) | 23.8 (22.4-28.0) | .47 |
| Time from ART initiation to sample collection (wk) | 31.3 (5-263) | 48.6 (48-51) | .80 |
| CD4 T cells per μL | 208 (74-357) | 246 (227-304) | .440 |
| CD19 B cells per μL | 124 (50-242) | NA | NA |
| Hemoglobin (g/dL) | 10.0 (8.5-11.5) | 12.8 (11.4-13.8) | .001 |
| Platelets (×103/μL) | 219 (115-328) | 258 (218-287) | .448 |
| HIV-VL (log10 IU/mL) | 1.8 (0.7-3.0) | 0.9 (0.7-1.8) | .078 |
| Ferritin (ng/mL) | 696 (376-1520) | 29 (17-38) | <.001 |
| CRP (mg/L) | 33.7 (10.5-73.8) | 2.0 (1.3-2.3) | <.001 |
| KSHV-VL (log10 copies per million cells) | 3.6 (2.7-4.6) | NA | NA |
| KAD subgroups, n | NA | NA | |
| KS | 10 (23.8) | ||
| MCD ± KS | 11 (26.1) | ||
| MCD and PEL ± KS | 5 (11.9) | ||
| KICS + KS | 11 (26.1) | ||
| PEL | 5 (11.9) | ||
| Prior therapy | 18 (42.9) | NA | NA |
Data represent medians with interquartile range for continuous variables and frequencies for categorical variables. The Wilcoxon test was used to compare continuous variables, whereas the Pearson χ2 test was used to compare frequencies. KSHV-VL represents copies per million PBMCs. KAD subtype is reported as single disease or an overlapping presentation. Prior therapy refers to immune modulation therapies or chemotherapy in the year before sample collection: doxorubicin, pomalidomide, cyclophosphamide, corticosteroids, and rituximab.
ART, antiretroviral therapy; BMI, body mass index; NA, not applicable.